Myriad Genetics announced it has entered into a definitive agreement to acquire select assets from Intermountain Precision Genomics’, or IPG, laboratory business, including the Precise Tumor Test, the Precise Liquid Test, and IPG’s CLIA-certified laboratory in St. George, Utah where the Precise Tumor Test is currently performed. The acquisition is expected to close on February 1, 2024, subject to customary closing conditions. By bringing the Precise Tumor and Precise Liquid tests in house, Myriad will open up new opportunities for innovation, growth, and continued development of its oncology portfolio. The financial terms of the deal were not disclosed but are not material to either Myriad or Intermountain Healthcare.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MYGN:
- Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
- Myriad Genetics Applauds New Germline Testing Guideline for Patients with Breast Cancer from ASCO-SSO
- Mesa Labs appoints Mark Capone to board of directors
- Myriad Genetics to Present at 42nd Annual J.P. Morgan Healthcare Conference
- Salesforce upgraded, Chipotle downgraded: Wall Street’s top analyst calls